Eledon Pharmaceuticals (<a>NASDAQ:ELDN</a> – <a>Get Free Report</a>) will likely be releasing its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect Eledon Pharmaceuticals to post earnings of ($0.28) per share for the quarter. \n\nEledon Pharmaceuticals (<a>NASDAQ:ELDN</a> – <a>Get Free Report</a>) last posted its earnings results on Thursday, March 20th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.32). During the same period in the prior year, the company earned ($1.00) EPS. On average, analysts expect Eledon Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year. \n\nEledon Pharmaceuticals Trading Down 7.4 % \n\nShares of <a>NASDAQ:ELDN</a> opened at $2.87 on Wednesday. The stock has a market capitalization of $171.86 million, a PE ratio of -1.43 and a beta of 0.08. Eledon Pharmaceuticals has a 1 year low of $2.00 and a 1 year high of $5.54. The firm has a fifty day moving average price of $3.32 and a 200 day moving average price of $3.98. \n\nWall Street Analyst Weigh In \n\nSeparately, Guggenheim assumed coverage on Eledon Pharmaceuticals in a report on Tuesday, January 28th. They set a “buy” rating and a $9.00 price objective on the stock. \n\nAbout Eledon Pharmaceuticals \n\nEledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).

Eledon Pharmaceuticals (ELDN) Expected to Announce Quarterly Earnings on Thursday

Eledon Pharmaceuticals is set to release Q1 2025 earnings results, with analysts expecting a loss of $0.28 per share, missing the consensus estimate. The company previously reported a loss of $0.64 per share in Q1 2024, while its stock has a market cap of $171.86 million and a negative PE ratio. Guggenheim recently assigned a 'buy' rating with a $9.00 price target.